CA
NZ
UK
AU
IND
US
Humana (NYSE:HUM) shares are trading sharply higher today, up 3.30% to $385.12, rebounding after a stretch of investor caution tied to the company's late-July second-quarter report. The company beat on adjusted EPS, posting $7.61 versus a $7.27 estimate, andRevenuerose 26.2% to $40.89 billion, but …
Liquidia (NASDAQ:LQDA) shares are tumbling nearly 10% today, down 9.85% to $79.38, despite the company reporting strong second-quarter 2026 results, with revenue of $171.7 million topping estimates of $168.5 million andNet Incomeof $74.7 million driven by a 31% quarter-over-quarter surge in YUTREPIA sales. The …
Molina Healthcare (NYSE:MOH) shares are surging today, up 4.61% to $203.51, as investors continue to react favorably to the company's July 22 second-quarter earnings beat. Adjusted EPS of $1.51 topped the $1.39 consensus, andRevenueof $10.87 billion came in slightly ahead of estimates, even as …
Replimune Group (NASDAQ:REPL) shares are rallying sharply today, up 12.54% to $15.36, near 52-week highs, as heavily shorted stock, with short interest around 58% of float, squeezes higher just two days after the company priced a $150 million equity offering at $12.06 per share …
Avalyn Pharma (NASDAQ:AVLN) shares are surging today, up 6.77% to $37.86, after the clinical-stage biopharmaceutical company reported second-quarter 2026 results that beat consensus loss-per-share estimates and highlighted completed enrollment of its pivotal Phase 2b MIST trial evaluating AP01, an inhaled formulation of pirfenidone, in …
COMPASS Pathways (NASDAQ:CMPS) shares rose sharply today, up 5.90% to $14.17, as analyst sentiment remained bullish following the company's Phase 3 psilocybin therapy data and continued progress toward a potential first-half 2027 FDA approval. The stock received a 'Moderate Buy' consensus rating from 17 …
GeoVax Labs (NASDAQ:GOVX), a penny stock, shares are trading lower today, down 4.61% to $0.73. The move comes as the clinical-stage biotechnology company recently highlighted the FDA's accelerated approval of Replimune's (NASDAQ:REPL) intratumoral cancer therapy, TUDRIQEV, in combination with checkpoint inhibitor nivolumab, framing the …
GMR Solutions (NYSE:GMRS) shares are surging today, up 12.02% to $13.33, as investors react to disclosed institutional buying and a reaffirmed Buy rating from J.P. Morgan analyst Benjamin Rossi, who maintained a $15 price target on the stock. Recent 13G and 13D filings revealed …
Cash and marketable securities stand at $164.3 million, enough to fund operations through the second quarter of 2028. Early Phase 1 data for the TF‑targeting ADC STRO‑004 revealed multiple partial responses and a favorable safety profile, underscoring the company’s advancing pipeline.
The results arrive as the firm continues to explore strategic alternatives after transitioning to a pure royalty model.
Please wait processing your request...